French biotechnology company PathoQuest has received CE mark for its iDTECT blood test for clinical identification of pathogens from blood samples.

The iDTECT blood test represents a next generation sequencing (NGS)-based metagenomics approach which has been developed to provide a clinically improved method of detection of bacteria and viruses in blood samples derived from patients suspected with infections or immunocompromised patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Hôpital Necker-Enfants Malades infectious and tropical diseases department chair and professor Olivier Lortholary said: “In some clinical situations, especially when a patient is immunocompromised, culture and PCR tests are often unable to provide sufficient information to select the most appropriate targeted anti-infective therapy.

"CE marking of the iDTECT Blood test is a major milestone for PathoQuest."

“With the availability of iDTECT Blood, clinicians will be able to expand their experience on the basis of the results already obtained in a proof-of-concept study completed at Necker-Enfants Malades and Européen Georges Pompidou hospitals (Paris, France) on a cohort of over 100 immuno-compromised patients.”

The iDTECT blood test uses PathoQuest’s proprietary methods to prepare blood samples and analyse it by leveraging the latest NGS-based technology to identify genomic sequences of pathogens in patient’s blood.

The genomic sequences, after being identified, are then compared to a comprehensive and curated database developed by PathoQuest which features genomics sequences from over 1,200 bacteria and viruses.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

PathoQuest CEO Jean-Francois Brepson said: “CE marking of the iDTECT Blood test is a major milestone for PathoQuest.

“It validates the robustness of our sample-to-BioIT analysis solution, driven by PathoQuest’s proprietary iDTECT database and software.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact